Aquestive Therapeutics (AQST) to Release Quarterly Earnings on Monday

Key Points

• Q1 2026 results due after the close Monday, May 11, with an earnings call on May 12 at 8:00 AM ET; analysts expect EPS of ($0.14) and revenue of $10.896 million.
• Last quarter Aquestive missed estimates (EPS ($0.26) vs. consensus ($0.13), revenue $13.02M vs. $13.28M), and analysts now forecast $0 EPS for the current and next fiscal years while consensus ratings remain a "Buy" with an average price target of $8.80 despite some mixed notes.
• Insiders have been net sellers (395,690 shares sold in the last 90 days, including large sales by Lori Braender and Melina Cioffi) while institutional ownership is ~32.45%; the stock traded at $4.25 (up 1.1%) with a market cap of $527.6M and a 1‑year range of $2.12–$7.55.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) will likely be posting its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Aquestive Therapeutics to post earnings of ($0.14) per share and revenue of $10.8960 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last posted its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The business had revenue of $13.02 million during the quarter, compared to analysts' expectations of $13.28 million. On average, analysts expect Aquestive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aquestive Therapeutics Trading Up 1.1%

NASDAQ:AQST traded up $0.05 on Monday, hitting $4.25. 218,856 shares of the company's stock traded hands, compared to its average volume of 3,740,455. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $7.55. The firm has a 50-day moving average price of $4.13 and a 200-day moving average price of $4.94. The company has a market cap of $527.61 million, a PE ratio of -5.44 and a beta of 1.50.

Insider Activity

In other news, insider Lori J. Braender sold 40,102 shares of the company's stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total transaction of $167,225.34. Following the completion of the transaction, the insider directly owned 442,879 shares in the company, valued at $1,846,805.43. The trade was a 8.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Melina Cioffi sold 25,311 shares of the company's stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $105,546.87. Following the transaction, the senior vice president owned 274,867 shares of the company's stock, valued at approximately $1,146,195.39. This trade represents a 8.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 395,690 shares of company stock valued at $1,650,027. Insiders own 6.81% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Aquestive Therapeutics by 30.8% during the third quarter. Vanguard Group Inc. now owns 5,662,132 shares of the company's stock worth $31,651,000 after buying an additional 1,333,627 shares during the last quarter. State Street Corp lifted its holdings in shares of Aquestive Therapeutics by 53.7% during the fourth quarter. State Street Corp now owns 2,462,778 shares of the company's stock worth $15,910,000 after buying an additional 860,562 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Aquestive Therapeutics by 13.4% during the fourth quarter. Geode Capital Management LLC now owns 2,368,092 shares of the company's stock worth $15,301,000 after buying an additional 280,144 shares during the last quarter. Federated Hermes Inc. lifted its holdings in shares of Aquestive Therapeutics by 159.4% during the fourth quarter. Federated Hermes Inc. now owns 2,032,822 shares of the company's stock worth $13,132,000 after buying an additional 1,249,044 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Aquestive Therapeutics by 19.1% during the fourth quarter. Millennium Management LLC now owns 1,535,369 shares of the company's stock worth $9,918,000 after buying an additional 246,040 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Wall Street Zen cut Aquestive Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, April 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Monday, April 20th. Lake Street Capital set a $6.00 price target on Aquestive Therapeutics in a research note on Tuesday, February 3rd. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They issued an "outperform" rating and a $8.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Aquestive Therapeutics currently has a consensus rating of "Buy" and an average price target of $8.80.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.